CITI/CALL/GILEAD SCIENCES/100/0.1/19.06.25 | Delayed Deutsche Boerse AG 05:08:01 2024-05-27 EDT | ||
| 0.006 EUR | -53.85% |
|
| 1 month | -70.45% | ||
| 3 months | -88.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-27 | 0.006 | -53.85% |
| 24-05-24 | 0.013 | +8.33% |
| 24-05-23 | 0.012 | -25.00% |
| 24-05-22 | 0.016 | +14.29% |
| 24-05-21 | 0.014 | -39.13% |
Delayed Quote Deutsche Boerse AG
Last update May 27, 2024 at 05:08 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Citi
|
| WKN | KH6VWV |
| ISIN | DE000KH6VWV1 |
| Date issued | 2023-06-20 |
| Strike | 100 $ |
| Maturity | 2025-06-19 (389 Days) |
| Parity | 10 : 1 |
| Emission price | 0.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.5 € |
|---|---|
| Lowest since issue | 0.004 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.68
USD
Average target price
82.77
USD
Spread / Average Target
+26.03%
- Stock Market
- Warrants
- Warrant
